Member Info for Borsaci06

you can score a goal from offside but wont count.
keep changing the goal post. " critically ill patients >>> ivermectin >>>> "

not saying that protocols are must-do
just sharing what is available on internet

here we go

Prevention and Treatment Protocols for COVID-19 >>>>>> as it says on the tin, Sng has been trialing

* MATH+ Hospital Treatment Protocol for COVID-19
https://covid19criticalcare.com/covid-19-protocols/math-plus-protocol/

* I-RECOVER Management Protocol for Long Haul COVID-19 Syndrome (LHCS)
https://covid19criticalcare.com/covid-19-protocols/i-recover-protocol/

* I-MASK+ Prevention & Early Outpatient Treatment Protocol for COVID-19
https://covid19criticalcare.com/covid-19-protocols/i-mask-plus-protocol/

* I-MASS – Prevention & At Home Treatment Mass Distribution Protocol for COVID-19
https://covid19criticalcare.com/covid-19-protocols/i-mass-protocol/

if memory serves me right, the trial did not meet the end point

" sharing is caring & sharing makes it more " mom used to say

reminded " The FLCCC Alliance "

https://covid19criticalcare.com/network-support/the-flccc-alliance/

they got 4 protocols for covid19
none of them include any type of INF

AZN itself said;

" The LAABs have been engineered with AstraZeneca’s proprietary half-life extension technology to increase the durability of the therapy for six to 12 months "

https://www.astrazeneca.com/media-centre/press-releases/2020/covid-19-long-acting-antibody-laab-combination-azd7442-rapidly-advances-into-phase-iii-clinical-trials.html

is it too naive to think;
developers, Otsuka and Lundbeck will get the licence for MTD211 Q-brexpiprazolein
after all,
Rexulti® (brexpiprazole) belongs to them

The five products are in an advanced stage of development and have a high potential to be among the three new COVID-19 therapeutics to receive authorisation by October 2021, the target set under the Strategy, provided the final data demonstrate their safety, quality and efficacy.

The products are:
A new COVID-19 indication for existing medicines:

baricitinib immunosuppresant (a medicine that reduces the activity of the immune system) from Eli Lilly: an application for extension of marketing authorisation for COVID-19 indication is under assessment

Newly developed monoclonal antibodies under rolling review - a regulatory tool to speed up the assessment of a promising medicine during a public health emergency:

combination of bamlanivimab and etesevimab from Eli Lilly: under rolling review
combination of casirivimab and imdevimab from Regeneron Pharmaceuticals, Inc. and F. Hoffman-La Roche, Ltd: under rolling review
regdanivimab from Celltrion: under rolling review
sotrovimab from GlaxoSmithKline and Vir Biotechnology, Inc.: under rolling review

https://ec.europa.eu/commission/presscorner/detail/en/ip_21_3299
Press release 29 June 2021
Brussels

https://www.genengnews.com/covid-19-candidates/astrazeneca-azd7442/
AZN have a proprietary half-life extension technology. ( making medicines Long-Acting )

NO, as sober as judge
placing done & dusted without obstacles to share price ( warrants ), guess some people not happy about
going forward, can see clear coast for 20 miles ( ~20 months )

think,
Otsuka got approval by FDA in 2015 & Japan in 2018
MTPH made it ( LAI ) long acting injectable for 90 days ( not like PLGA 40 days )
comes with benefits to Patients, Health Care and Criminal Justice System

Excellent Q-Sphera drug loading achieved (20%) enabling up to 90 days sustained delivery
Outperforms drug suspension approach used for other AAPs, which relies on the poor solubility and slow dissolution of drug particles at the injection site

Overall, brexpiprazole achieved in vivo sustained release from
PLGA microspheres for up to 40 days.

Conclusion: A PLGA microsphere loaded with brexpiprazole was successfully developed and demonstrated potential for extended-release of therapeutics for schizophrenia treatment.

Bangqing Wu, Lijun Wu, Yingju He, Zongning Yin, Li Deng
May 25, 2021

Conclusions: Patients with schizophrenia or schizoaffective disorder who were initiated on a LAI antipsychotic medication, specifically PP1M, were less likely to have an encounter with the criminal justice system compared with a similar time period before the initiation of LAI treatment.
May 19, 2021
Madhav P. Bhatta, Saroj Bista, Antoine C. El Khoury, Eric G. Hutzell, Neeta Tandon, Douglas Smith

Patients with schizophrenia who switch from oral antipsychotics to long-acting injectables lower their risk of suicide by nearly 47%.
Megan Brooks
May 18, 2021
Long-Acting Injectable Antipsychotics Cut Suicide Death Risk in Half

In patients with early-stage schizophrenia, use of a long-acting antipsychotic
produced a 44% reduction in the incidence rate of first hospitalizations compared with use of antipsychotics as conventionally delivered.

In Early Schizophrenia, Long-Acting Injectable Antipsychotic Treatment Lengthened Time to First Hospitalization
Posted: March 25, 2021

Lyndra Inc raised $60.5M in Series C to push its long-acting schizophrenia pill
through a pivotal trial. This brings Lyndra's funding to over $160M, which will be used to reformulate existing
daily pills into weekly ones.

Otsuka Receives Approval in Japan for the Manufacture and
Sale of New Antipsychotic Drug Rexulti® Tablets for Schizophrenia
January 19, 2018

The drug was developed by Otsuka and Lundbeck, and is considered to be a successor[7] of Otsuka's top-selling atypical antipsychotic aripiprazole (Abilify).

The drug was approved by the U.S. Food and Drug Administration (FDA) on July 10, 2015, for the treatment of schizophrenia

In November 2011, Otsuka Pharmaceutical and Lundbeck announced a global alliance.[13] Lundbeck gave Otsuka an upfront payment of $200 million, and the deal includes development, regulatory and sales payments, for a potential total of $1.8 billion. Specifically for OPC-34712, Lundbeck will obtain 50% of net sales in Europe and Canada and 45% of net sales in the US from Otsuka

company said so many things over the years,
one of them was:
recently, they were not going to do clinical trials themselves unless it is paid by others ( partners, collaborators ),
yet they riased to do so.
In away they are correct,
paid by PI + II but not partners, .......

imho

more than 50% dilution

so we are supposed to accept it without validation from other parties, just because company says The breakthrough data

"" 12 yrs since I left! "" said Mark Barry, founded and set up Q Chip.
but
no pruduct in market or pIII-IV

"" Company expects to initiate a Phase II study in DIPG later this year ""
who will fund this
have they enough panobinostat supply untill becoming a generic in 2025

* issue price of £0.27 per Unit
discount of approximately 35% to the closing middle market price of £0.415 per existing ordinary share on 15 May 2020
* issue price of £0.27 per share
a discount of approximately 32% to the closing middle market price of £0.395 per existing ordinary share on 24 July 2020

unless partner sign a licence deal before 4th Q
raise will be here

as said by some, Viveka`s expertise in drug delivery kept me interesting in mtph,
unfortunately not posting anymore ( think , lost interest in company)

instead of buyers,
they got partners / Collaboration
also almost all holders ( shares & warrants ... ) had to declare

RNS Number : 8199T
23 July 2020
Corporate Update & Formal Sale Process Termination